RSS Sandoz To Pay $275 Mln To Resolve US Generic Drug Litigation, Plans $265 Mln Provision; Backs View

Currently reading:
 RSS Sandoz To Pay $275 Mln To Resolve US Generic Drug Litigation, Plans $265 Mln Provision; Backs View

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,209
Likes
1,916
Credits
32,769©
Cash
0$
Sandoz Group AG, a Swiss company specializing in generic and biosimilar medications, revealed on Tuesday that it has agreed to pay $275 million to settle an antitrust class action lawsuit in the United States involving generic drugs. This settlement is with the class of end payer plaintiffs.

The company has also reserved $265 million to potentially settle further claims from opt-out plaintiffs and State Attorneys General. These financial measures will be reflected in Sandoz's financial statements for 2024, yet they will not impact its current full-year 2024 projections or its medium-term outlook.

Sandoz US has reached a settlement with the plaintiffs that outlines steps to resolve the legal dispute, but the agreement does not entail any admission of guilt by Sandoz. This agreement involves Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. with the end payer plaintiffs in the multi-district litigation known as In re Generic Pharmaceuticals Pricing Antitrust Litigation, currently before the US District Court for the Eastern District of Pennsylvania.

The settlement addresses all damage claims from the end payer class, which includes certain consumers, insurers, and health and welfare funds, along with employee benefit plans and other entities who have paid for or reimbursed drug sales. As per the agreement, Sandoz will pay the full $275 million by December 31, 2024, in return for a comprehensive release of claims by the class members involved in this litigation.

Court approval is essential for this settlement to proceed, as mandated for class settlements under US law. This agreement succeeds previous settlements with the US Department of Justice in 2020 and 2021 and with the direct purchaser plaintiffs’ class in February 2024.

The other claims still pending are related to alleged anti-competitive practices in the US market, filed by certain US States and Territories as well as the indirect reseller plaintiff class and individual plaintiffs in the multidistrict litigation.

Beyond the US antitrust litigation, Sandoz Inc. and its affiliates, Sandoz Canada Inc. and Fougera Pharma, are also implicated in a class action lawsuit in Ontario, Canada, over allegedly fixing prices in the Canadian generic pharmaceuticals market.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom